The MicroCoat platform technology employs a fluid bed coating process to produce individually coated drug micropellets, that regulate the rate of drug release, enabling taste masking and extended release as relevant. The technology is investigated for an application to a malaria treatment for paediatric populations in LMICs through the support of a UnitaidExplore grant . MicroCoat AS/AQ combines into a fixed-dose combination of taste-masked anti-malarial drugs artesunate and amodiaquine, offering ease of administration and improved palatability for children compared to marketed products (especially for amodiaquine, which is very bitter and thereby challenging for use in children), while maintaining the same efficacy and safety. The formulation has been designed to be suitable for infants and young children for the treatment of uncomplicated P. falciparum malaria in LMICs, by ensuring not only palatability, but also easier swallowing and more flexible dosing than standard of care. The product is stable at accelerated and long-term conditions and is in early clinical development.